• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Surrozen Inc.

    8/8/25 4:24:11 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRZN alert in real time by email
    S-8 1 srzn-20250808.htm S-8 S-8

     

    As filed with the U.S. Securities and Exchange Commission on August 8, 2025

    Registration No. 333-


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Surrozen, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Delaware

    30-1374889

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

     

    171 Oyster Point Blvd, Suite 400

    South San Francisco, CA 94080

    (650) 489-9000

    (Address of principal executive offices, including zip code)

     

    Surrozen, Inc. 2025 Equity Inducement Plan

    (Full titles of the plans)

     

    Craig Parker

    President and Chief Executive Officer

    Surrozen, Inc.

    171 Oyster Point Blvd, Suite 400

    South San Francisco, CA 94080

    (650) 489-9000

    (Name, address and telephone number, including area code, of agent for service)

     

    Copy to:

    John T. McKenna

    Jonie I. Kondracki

    Cooley LLP

    3175 Hanover Street

    Palo Alto, CA 94304

    (650) 843-5000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by Surrozen, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering 250,000 shares of the Registrant’s common stock, par value $0.0001 per share, to be issued pursuant to the Registrant’s 2025 Equity Inducement Plan (the “2025 Plan”).

     

    Part I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    As permitted by the rules of the Commission, this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the 2025 Plan, as required by Rule 428(b)(1) under the Securities Act of 1933, as amended.

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a)

    The Registrant’s Annual Report on Form 10-K (File No. 001-39635) for the year ended December 31, 2024 filed with the Commission on March 31, 2025.

    (b)

    The Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 2, 2025 (but only with respect to information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024)

    (c)

    The Registrant’s Quarterly Report on Form 10-Q (File No. 001-39635) for the quarter ended March 31, 2025, filed with the Commission on May 9, 2025.

    (d)

    The Registrant’s Quarterly Report on Form 10-Q (File No. 001-39635) for the quarter ended June 30, 2025, filed with the Commission on August 8, 2025.

     

    (e)

    The Registrant’s Current Reports on Form 8-K (File No. 001-39635) filed with the Commission on March 28, 2025 and May 15, 2025.

    (f)

    The description of the Registrant’s common stock which is contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on March 31, 2025 (File No. 001-39635).

     

    (g)

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Names Experts and Counsel.

     

    Not applicable.

     


    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law (the “DGCL”) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent of the Registrant. The DGCL provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaws, agreement, vote of stockholders or disinterested directors or otherwise. The Registrant’s certificate of incorporation and bylaws provide for indemnification by the Registrant of its directors and officers to the fullest extent permitted by the DGCL.

     

    The Registrant has entered into indemnification agreements with each of its directors and executive officers to provide contractual indemnification in addition to the indemnification provided in the Registrant’s certificate of incorporation. Each indemnification agreement provides for indemnification and advancements by the Registrant of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the Registrant or, at the Registrant’s request, service to other entities, as officers or directors to the maximum extent permitted by applicable law.

     

    The Registrant also maintains standard policies of insurance under which coverage is provided (1) to its directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, while acting in their capacity as directors and officers of the Registrant, and (2) to the Registrant with respect to payments which may be made by the Registrant to such officers and directors pursuant to any indemnification provision contained in the Registrant’s certificate of incorporation and bylaws or otherwise as a matter of law.

    Item 7. Exemption From Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

     

     

     

     

     

     

     

     

     

     

    Exhibit
    Number

    Incorporated by Reference

    Exhibit Description

    Form

    File No.

    Exhibit

    Filing Date

     

     

     

     

     

     

     4.1

    Certificate of Incorporation of Surrozen, Inc.

    8-K

    001-39635

    3.1

    August 17, 2021

     4.2

    Certificate of Amendment to the Certificate of Incorporation of Surrozen, Inc.

    8-K

    001-39635

    3.1

    December 13, 2023

     4.3

    Amended and Restated Bylaws of Surrozen, Inc.

    8-K

    001-39635

    3.1

    October 13, 2023

     4.4

    Specimen Warrant Certificate.

    S-1/A

    333-249394

    4.3

    October 13, 2020

     4.5

     

    Amended and Restated Warrant Agreement, dated as of March 31, 2023, by and between Surrozen, Inc. and Continental Stock Transfer & Trust Company.

     

    10-K

     

    001-39635

     

    4.6

     

    March 31, 2023

     5.1*

     

    Opinion of Cooley LLP.

     

     

     

     

     

     

     

     

     23.1*

     

    Consent of Ernst & Young LLP, independent registered public accounting firm.

     

     

     

     

     

     

     

     

     23.2*

     

    Consent of Cooley LLP (included in Exhibit 5.1 hereto).

     

     

     

     

     

     

     

     

     24.1*

     

    Power of Attorney (included on the signature page hereto).

     

     

     

     

     

     

     

     

     99.1*

     

    Surrozen, Inc. 2025 Equity Inducement Plan.

     

     

     

     

     

     

     

     

     107*

     

    Filing Fee Table

     

     

     

     

     

     

     

     

     

    * Filed herewith.

     

    Item 9. Undertakings.

    1.

    The undersigned registrant hereby undertakes:

    (a)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i)

    To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective registration statement; and

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     


     

    provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

    (b)

    That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2.

    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3.

    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on August 8, 2025.

     

     

     

    SURROZEN, INC.

     

     

    By:

    /s/ Craig Parker

     

    Craig Parker

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Craig Parker and Charles Williams, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

     

     

    /s/ Craig Parker

    Craig Parker

    President and Chief Executive Officer and Director

    (Principal Executive Officer)

    August 8, 2025

     

     

     

    /s/ Charles Williams

    Charles Williams

    Chief Financial Officer and Chief Operating Officer

    (Principal Financial and Accounting Officer)

    August 8, 2025

     

     

     

    /s/ David J. Woodhouse, Ph.D.

    David J. Woodhouse, Ph.D.

    Chair of the Board of Directors

    August 8, 2025

     

     

     

    /s/ Anna Berkenblit, M.D.

    Director

    August 8, 2025

    Anna Berkenblit, M.D.

     

     

     

     

     

    /s/ Eric Bjerkholt

    Director

    August 8, 2025

    Eric Bjerkholt

     

     

     

     

     

    /s/ Christopher Chai

    Director

    August 8, 2025

    Christopher Chai

     

     

     

     

     

    /s/ Mary Haak-Frendscho, Ph.D.

    Director

    August 8, 2025

    Mary Haak-Frendscho, Ph.D.

     

     

     

     

     

    /s/ Shao-Lee Lin, M.D., Ph.D.

    Director

    August 8, 2025

    Shao-Lee Lin, M.D., Ph.D.

     

     

     

     

     

     

     

    /s/ Mace Rothenberg, M.D.

     

    Director

     

    August 8, 2025

    Mace Rothenberg, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Tim Kutzkey, Ph.D.

     

    Director

     

    August 8, 2025

    Tim Kutzkey, Ph.D.

     

     

     

     


    Get the next $SRZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRZN

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Buy
    H.C. Wainwright
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    10/11/2021$11.00Buy
    B of A Securities
    9/15/2021$20.00Buy
    Guggenheim
    9/7/2021$19.00Buy
    Stifel
    More analyst ratings

    $SRZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor conference. Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025 Surrozen Fireside Chat at 5:00 – 5:30 AM Pacific Time/8:00 – 8:30 AM Eastern Time Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentati

    8/28/25 4:15:25 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

    8/8/25 4:05:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor ophthalmology focused conference. H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 Surrozen presentation will be available beginning at 7:00 AM Eastern Time Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen websi

    8/6/25 4:30:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    SEC Filings

    View All

    Surrozen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Surrozen, Inc./DE (0001824893) (Filer)

    8/29/25 4:58:02 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Surrozen Inc.

    424B5 - Surrozen, Inc./DE (0001824893) (Filer)

    8/29/25 4:55:18 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

    SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    8/14/25 4:36:25 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec. Vice President, Research Li Yang was granted 400 shares, increasing direct ownership by 3% to 13,043 units (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    6/16/25 6:58:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO and COO Williams Charles O was granted 400 shares, increasing direct ownership by 4% to 9,382 units (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    6/16/25 6:47:48 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Parker Craig C was granted 400 shares, increasing direct ownership by 6% to 7,024 units (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    6/16/25 6:44:45 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Surrozen with a new price target

    H.C. Wainwright initiated coverage of Surrozen with a rating of Buy and set a new price target of $32.00

    1/30/25 7:17:42 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen upgraded by Guggenheim with a new price target

    Guggenheim upgraded Surrozen from Neutral to Buy and set a new price target of $45.00

    1/3/25 7:50:23 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B of A Securities initiated coverage on Surrozen with a new price target

    B of A Securities initiated coverage of Surrozen with a rating of Buy and set a new price target of $11.00

    10/11/21 7:02:26 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iii Gp, Lp bought $11,999,991 worth of shares (1,034,482 units at $11.60) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/28/25 8:57:08 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Column Group Iii Gp, Lp bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

    4/A - Surrozen, Inc./DE (0001824893) (Issuer)

    4/17/24 4:14:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kutzkey Tim bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

    4/A - Surrozen, Inc./DE (0001824893) (Issuer)

    4/17/24 4:10:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Leadership Updates

    Live Leadership Updates

    View All

    Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

    8/8/25 4:05:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

    SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

    4/5/23 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

    9/23/21 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/14/24 4:34:39 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/13/24 5:42:02 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/8/24 11:26:54 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Financials

    Live finance-specific insights

    View All

    Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

    Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023

    3/22/23 4:01:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

    SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress. Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast. Ab

    3/20/23 4:30:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care